Latest News

• share
• favorite_border

On behalf of the nation's radiation oncologists and the more than one million people with cancer they will treat this year, the American Society for Radiation Oncology (ASTRO) applauded today's House passage of bipartisan federal legislation that would rein in restrictive prior authorization practices that delay patient access to critical cancer treatments.

• share
• favorite_border

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients with isocitrate dehydrogenase (IDH)-mutant grade 2 and grade 3 diffuse glioma. Evidence-based recommendations outline the multidisciplinary planning and delivery techniques to manage this subset of central nervous system (CNS) tumors.

• share
• favorite_border

The American Society for Radiation Oncology (ASTRO) today expressed its support for President Joseph R. Biden Jr.’s intended appointment of Monica Bertagnolli, MD, as director of the National Cancer Institute (NCI), with the following statement from Laura A. Dawson, MD, FASTRO, Chair of the ASTRO Board of Directors.

• share
• favorite_border

The members of the American Society for Radiation Oncology (ASTRO) elected seven leading radiation oncologists to ASTRO’s Board of Directors, including Howard Sandler, MD, FASTRO, as President-elect. The officers will begin their terms in October during ASTRO’s 64th Annual Meeting in San Antonio.

• share
• favorite_border

The American Society for Radiation Oncology (ASTRO) selected 27 distinguished members to receive the ASTRO Fellow (FASTRO) designation. The 2022 Fellows will be recognized at an awards ceremony during ASTRO’s 64th Annual Meeting this fall.

• share
• favorite_border

Registration is now open for the American Society for Radiation Oncology's (ASTRO) 64th Annual Meeting, to be held at the Henry B. Gonzalez Convention Center in San Antonio, October 23-26, 2022. Media registration is available at www.astro.org/astro2022press, and general registration is available at www.astro.org/annualmeeting.

• share
• favorite_border

The American Society for Radiation Oncology delivered comments to CMS following a proposed indefinite delay for the radiation oncology APM. Recommendations outline actionable steps to stabilize Medicare reimbursement, prioritize health equity, reduce unnecessary administrative burden and improve cancer outcomes.

• share
• favorite_border

The American Society for Radiation Oncology (ASTRO) recently hired Chris Neumann as its new Vice President of Learning and Education, and Kirsta Suggs as its first Director of Diversity, Equity and Inclusion (DEI).

• share
• favorite_border

Radiation oncologists will meet with congressional leaders and staff today to ask for their support of policies to bolster access and equity in cancer care. Today’s American Society for Radiation Oncology (ASTRO) Advocacy Day is the first to be held in-person since the start of the COVID-19 pandemic.

• share
• favorite_border

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat patients with brain metastases from non-hematologic solid tumors. The guideline, which updates ASTRO’s original 2012 guideline to reflect recent research developments, is published in Practical Radiation Oncology.

• share
• favorite_border

American Society for Radiation Oncology (ASTRO) response to the CMS decision to delay the start of the Radiation Oncology Alternative Payment Model (RO Model)

• share
• favorite_border

A large, multi-institutional study demonstrates that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. Findings will be presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.

• share
• favorite_border

A new phase II trial finds that PET scans obtained before and midway through treatment for p16+ oropharynx cancer can guide de-escalated chemoradiotherapy, resulting in fewer short-term side effects. Findings will be presented today at the 2022 Multidisciplinary Head and Neck Cancers Symposium.

• share
• favorite_border

A multi-method artificial intelligence (AI) model accurately detects and stages thyroid cancer through analysis of routine ultrasound images, presenting a low-cost, non-invasive option for personalized treatment. Findings will be presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.

• share
• favorite_border

The American Society for Radiation Oncology (ASTRO) issued a statement from ASTRO Board of Directors Chair Laura A. Dawson, MD, FASTRO, in response to today's announcement that President Joe Biden will reignite the Cancer Moonshot initiative to accelerate the rate of progress in the nation's fight against cancer.

• share
• favorite_border

American Society for Radiation Oncology (ASTRO) response to the Supporting Health Care Providers During the COVID-19 Pandemic Act, which includes a provision to delay the start of the Radiation Oncology Alternative Payment Model (RO Model): "While we are grateful for the delay, our focus remains on the reforms needed for the model to be successful. ... This delay creates a critical window of opportunity for Congress to address the RO Model’s flaws."

• share
• favorite_border

The American Society for Radiation Oncology (ASTRO) issued the following statement today in response to the 2022 Medicare Physician Fee Schedule (MPFS) and Hospital Outpatient Prospective Payment System (HOPPS) final rules announced by the Centers for Medicare and Medicaid Services (CMS).

• share
• favorite_border

The time required to secure prior authorization approvals for radiation therapy treatments equates to a financial impact of more than $40 million annually for academic medical centers, according to a new study. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

• share
• favorite_border

A new study shows that system-level changes to the way cancer care is delivered can also eliminate Black-white disparities in survival from early-stage lung and breast cancer. By identifying and addressing obstacles that kept patients from finishing radiation treatments for cancer, the intervention improved five-year survival rates for all patients and erased the survival gap between Black and white patients. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

• share
• favorite_border

A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy. The study, which examined biopsy samples collected from three large, randomized clinical trials, indicates that physicians potentially can use genetic test scores to personalize treatment for men with the most aggressive form of prostate cancer. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.